Clinicians

Welcome to the first CTGCT Newsletter featuring a selection of the articles we're most proud of in the last year.

case study on the Braintree Manufacturing Innovation Centre (Braintree MIC), recently licensed by the MHRA. This state-of-the-art facility is revolutionizing the field of advanced therapy medicinal products (ATMPs) by providing cutting-edge infrastructure and expertise ...

From the 16th of October 2024 to the 18th the Kemijski Inštitut hosted the 1st CTGCT Conference

Translational Medicine Ecosystem Ljubljana, Slovenia, Friday 18th October 2024, Location: Kemijski inštitut online transmission of event: webex teleconferencing link   8:30 Registration 9:00 Welcome Addresses Gregor Anderluh, National Institute of Chemistry Mojca Benčina, CTGCT ...

The CTGCT hosted representatives from ERN ITHACA and SATB2 Europe to discuss collaborative efforts in rare disease research and treatment. The meeting focused on developing innovative therapies and strengthening connections between researchers, clinicians, and ...

The European Commission recently held its sixth regional event in Budapest, focusing on the upcoming Health Technology Assessment (HTA) regulation. Set to launch in January 2025, this new framework aims to streamline the evaluation ...

Assoc. Prof Dr Mojca Benčina, head of the newly founded Slovenian Centre for the Technologies of Gene and Cell Therapy (CTGCT), gave a speech at the recent 50th Annual Meeting of the European Society ...

Our partner University College London (UCL) have produced a great short brochure (link) showing the strength and depth  of their pipeline of ATMPs. They use a managed portfolio approach in which they support ~100 ...

The CTGCT organised its first Panel Discussion on 29 May entitled: ATMP Regulation. The main takeaway from the very successful session was that the strong potential of the Slovenian ecosystem requires the will to ...

At the Bespoke Gene Therapy Consortium (BGTC, website), a consortium for the treatment of rare monogenetic diseases, they aim to treat neglected diseases with a very small number of patients with a focus solely ...